论文部分内容阅读
目的探讨阿托伐他汀对脑梗死患者血脂及高敏C反应蛋白(hs-CRP)值的影响。方法选取38例脑梗死合并高脂血症的患者,随机分为2个组,即阿托伐他汀组(20例)和辛伐他汀(18例)组,观察患者用药前后血脂及hs-CRP的变化。结果患者在用药4周后,阿托伐他汀组和辛伐他汀组血清中甘油三酯、总胆固醇、低密度脂蛋白均显著降低(P<0.05),差异有统计学意义;阿托伐他汀组和辛伐他汀组hs-CRP均显著降低(P<0.05),但阿托伐他汀组降低更为明显(P<0.05)。结论阿托伐他汀可在短时间内降低脑梗死患者的血脂及hs-CRP值,从而降低脑血管疾病的发生。
Objective To investigate the effect of atorvastatin on serum lipids and high-sensitivity C-reactive protein (hs-CRP) in patients with cerebral infarction. Methods Thirty-eight patients with cerebral infarction and hyperlipidemia were randomly divided into 2 groups: atorvastatin group (20 cases) and simvastatin group (18 cases). The levels of serum lipids and hs-CRP The change. Results After 4 weeks of treatment, the levels of triglyceride, total cholesterol and low density lipoprotein in atorvastatin group and simvastatin group were significantly decreased (P <0.05), and the difference was statistically significant. Atorvastatin The hs-CRP levels in the simvastatin group and the simvastatin group were significantly decreased (P <0.05), but those in the atorvastatin group were more significantly decreased (P <0.05). Conclusions Atorvastatin can reduce the blood lipid and hs-CRP in patients with cerebral infarction in a short time and thus reduce the incidence of cerebrovascular disease.